Cann Group Limited (Cann) is launching a range of imported medicinal cannabis products to be distributed to approved Special Access Scheme (SAS) patients by Symbion Pty Ltd.
Cann’s agreement with Symbion, suppliers of healthcare services and products to more than 4000 retail pharmacies and 1300 hospitals throughout Australia, will ensure that products can be supplied through approved pathways to patients who have been approved via the SAS for medicinal cannabis treatment.
Symbion will carry Cann’s full range of imported products, for supply to approved SAS patients in line with each state’s legislative requirements.
Cann said it is making progressing in its product manufacturing validation program with IDT Australia Ltd, and expects to launch its first locally sourced and manufactured formulations in Q1 2020.
The Company has also received its first shipment of a high THC oil formulation, imported from strategic partner Aurora Cannabis in Canada. Permits are in place for the import and supply of an additional five product presentations being supplied by Aurora.
Cann Group CEO, Peter Crock, said the Company is now entering the commercialisation phase, having successfully established a reliable cultivation and production capability.
“We are now operating our existing Southern and Northern production facilities at full capacity, with in excess of 40 harvests now completed, and we are advancing our product manufacturing capabilities with IDT Australia”, he said.
In addition to finished product formulations, Cann is working with a network of Australian compounding pharmacies to develop the capacity to produce compounded products specifically formulated for individual patient needs.
“Cann’s development and production expertise – together with the specialist manufacturing capabilities provided by our partner, IDT Australia – ensures Australian patients will have access to high quality and safe medicinal cannabis products”, Mr Crock said.
“We are well underway with our major expansion program near Mildura, which is expected to be commissioned towards the end of next calendar year, and should consolidate Cann’s position as the leading local producer, with ample capacity to meet local patient needs.”
